Rasbach Kyle A, Arrington David D, Odejinmi Sina, Giguere Chris, Beeson Craig C, Schnellmann Rick G
Department of Biomedical and Pharmaceutical Sciences, Center for Cell Death, Injury, and Regeneration, South Carolina College of Pharmacy, Medical University of South Carolina, Charleston, South Carolina 29425, USA.
J Med Chem. 2009 Jan 8;52(1):181-8. doi: 10.1021/jm800735d.
Calpain 10 has been localized to the mitochondria and is a key mediator of Ca(2+) induced mitochondrial dysfunction. A peptide screen followed by a series of modifications identified the homodisulfide form of CYGAK (CYGAK)(2) as an inhibitor of calpain 10 while showing no inhibitory activity against calpain 1. Methylation or truncation of the N-terminal cysteine significantly reduced the inhibitory activity of (CYGAK)(2) and inhibition was reversed by reducing agents, suggesting that CYGAK forms a disulfide with a cysteine near the active site. Data suggests CYGAK may be a P' calpain inhibitor and may achieve its specificity through this mechanism. CYGAK inhibited calpain activity in intact mitochondria, renal cells, and hepatocytes, prevented Ca(2+) induced cleavage of NDUFV2, and blocked Ca(2+) induced state III dysfunction. (CYGAK)(2) is the first P' specific calpain inhibitor and will be a valuable tool to prevent Ca(2+) induced mitochondrial dysfunction and explore the function of calpain 10.
钙蛋白酶10定位于线粒体,是钙离子诱导的线粒体功能障碍的关键介质。通过肽筛选及一系列修饰,确定CYGAK的同型二硫键形式(CYGAK)₂为钙蛋白酶10的抑制剂,而对钙蛋白酶1无抑制活性。N端半胱氨酸的甲基化或截短显著降低(CYGAK)₂的抑制活性,还原剂可逆转抑制作用,这表明CYGAK与活性位点附近的半胱氨酸形成二硫键。数据表明CYGAK可能是一种P'钙蛋白酶抑制剂,并可能通过该机制实现其特异性。CYGAK抑制完整线粒体、肾细胞和肝细胞中的钙蛋白酶活性,防止钙离子诱导的NDUFV2裂解,并阻断钙离子诱导的状态III功能障碍。(CYGAK)₂是首个P'特异性钙蛋白酶抑制剂,将成为预防钙离子诱导的线粒体功能障碍及探索钙蛋白酶10功能的宝贵工具。